Table 5.

Absolute and relative risk of dying from breast cancer according to HER2 status and amplification of MRPS23

	MRPS23−a/HER2−	MRPS23−/HER2+c	MRPS23+b/HER2−	MRPS23+/HER2+
Cum. risk after 5 years (%) (95% CI)	18 (15–22)	44 (32–58)	12 (4–32)	53 (33–76)
Cum. risk after 10 years (%) (95% CI)	28 (25–32)	47 (36–61)	23 (11–44)	63 (42–83)
HR, unadjusted (95% CI)	1.0	1.6 (1.1–2.4)	0.6 (0.3–1.4)	2.6 (1.5–4.5)
HR adjusted for age (95% CI)	1.0	1.7 (1.1–2.5)	0.6 (0.3–1.4)	2.6 (1.5–4.8)
HR adjusted for grade (95% CI)	1.0	1.2 (0.8–1.8)	0.5 (0.2–1.1)	2.3 (1.3–4.0)
HR adjusted for stage (95% CI)	1.0	1.9 (1.3–2.8)	0.6 (0.3–1.4)	1.8 (1.0–3.3)
HR adjusted for Ki67 (95% CI)	1.0	1.3 (0.9–1.9)	0.5 (0.2–1.0)	2.2 (1.3–3.0)
HR adjusted for HER2 (95% CI)	1.0	1.6 (1.1–2.4)	0.6 (0.3–1.4)	2.6 (1.5–4.5)

Cum. risk cumulative risk, CI confidence interval, HR hazard ratio

^aMPR23− : MPRS23/CEP17 ratio < 2 and MRPS23 mean < 6

^bMRPS23 + : MRPS23/CEP17 ratio ≥ 2 and/or MRPS23 mean ≥ 6

^cHER2/CEP17 ratio ≥ 2 or intense membranous staining (IHC 3+) in > 10% of tumour cells